Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) 1/2 Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Fulvestrant (Primary) ; Selumetinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 14 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2020.
- 14 Dec 2013 Primary endpoint 'Disease-control-rate' has not been met.